199 related articles for article (PubMed ID: 36920736)
1. In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins.
Leidenmühler P; Höfinghoff J; Haider N; Brachtl G; Weiller M; Bilic I; Gangadharan B
Drug Deliv Transl Res; 2023 Sep; 13(9):2367-2377. PubMed ID: 36920736
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
Wasserman RL
Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
[TBL] [Abstract][Full Text] [Related]
3. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
Sanford M
BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
[TBL] [Abstract][Full Text] [Related]
4. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
Li Z; Nagy A; Lindner D; Duff K; Garcia E; Ay H; Rondon JC; Yel L
J Clin Immunol; 2024 Jun; 44(7):148. PubMed ID: 38896141
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL; Melamed I; Kobrynski L; Puck J; Gupta S; Doralt J; Sharkhawy M; Engl W; Leibl H; Gelmont D; Yel L
Immunotherapy; 2016 Oct; 8(10):1175-86. PubMed ID: 27468136
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
[No Abstract] [Full Text] [Related]
9. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
[TBL] [Abstract][Full Text] [Related]
10. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.
Wasserman RL
J Clin Immunol; 2012 Dec; 32(6):1153-64. PubMed ID: 22828788
[TBL] [Abstract][Full Text] [Related]
11. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study.
Wasserman RL;
Adv Ther; 2020 Apr; 37(4):1536-1549. PubMed ID: 32124273
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
14. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
[TBL] [Abstract][Full Text] [Related]
15. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency.
Jolles S
Immunotargets Ther; 2013; 2():125-33. PubMed ID: 27471693
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
18. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.
Wasserman RL
Immunotherapy; 2014; 6(5):553-67. PubMed ID: 24896624
[TBL] [Abstract][Full Text] [Related]
19. Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein.
Kang DW; Oh DA; Fu GY; Anderson JM; Zepeda ML
J Pharmacol Toxicol Methods; 2013; 67(3):140-7. PubMed ID: 23376811
[TBL] [Abstract][Full Text] [Related]
20. Use of computed tomography to assess subcutaneous drug dispersion with recombinant human hyaluronidase PH20 in a swine model.
Connor RJ; Taverna DM; Thrall K; LaBarre MJ; Kang DW
J Pharmacol Toxicol Methods; 2020; 106():106936. PubMed ID: 33191187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
